Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2009

Magro CM, Iwenofu OH, Kerns MJ, Kearns MJ, Nuovo GJ, Dyrsen ME, et al. Fulminant and accelerated presentation of dermatomyositis in two previously healthy young adult males: a potential role for endotheliotropic viral infection. J Cutan Pathol. 2009;36(8):853-8.

Sboner A, Karpikov A, Chen G, Smith M, Mattoon D, Dawn M, et al. Robust-linear-model normalization to reduce technical variability in functional protein microarrays. J Proteome Res. 2009;8(12):5451-64.

Josefowicz SZ, Wilson CB, Rudensky AY. Cutting edge: TCR stimulation is sufficient for induction of Foxp3 expression in the absence of DNA methyltransferase 1. J Immunol. 2009;182(11):6648-52.

Schleicher M, Yu J, Murata T, Derakhshan B, Atochin D, Qian L, et al. The Akt1-eNOS axis illustrates the specificity of kinase-substrate relationships in vivo. Sci Signal. 2009;2(82):ra41.

Sholl LM, Yeap BY, A Iafrate J, Holmes-Tisch AJ, Chou Y-, Wu M-, et al. Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res. 2009;69(21):8341-8.

Daniele L, Cassoni P, Bacillo E, Cappia S, Righi L, Volante M, et al. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol. 2009;4(6):684-8.

Du Y-, Klimstra DS, Varmus H. Activation of PyMT in beta cells induces irreversible hyperplasia, but oncogene-dependent acinar cell carcinomas when activated in pancreatic progenitors. PLoS One. 2009;4(9):e6932.

El-Sibai MF, Cohen C, Nassar A, Bryant SC, Siddiqui MT. Predictive markers in primary breast cancer compared with lymph node and bloodspread metastases. Int J Physiol Pathophysiol Pharmacol. 2009;1(1):57-63.

Moscat J, Diaz-Meco MT, Wooten MW. Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex. Cell Death Differ. 2009;16(11):1426-37.

Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, et al. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res. 2009;69(19):7803-10.